North,American,Seal,Health Household , Health Care , First Aid,kula.hacca.jp,$9,Chest,Vent,Rescue,/moderna-ceo-predicts-pandemic-could-be-over-in-a-year/,HyFin,by North,American,Seal,Health Household , Health Care , First Aid,kula.hacca.jp,$9,Chest,Vent,Rescue,/moderna-ceo-predicts-pandemic-could-be-over-in-a-year/,HyFin,by $9 HyFin Vent Chest Seal by North American Rescue Health Household Health Care First Aid HyFin Vent Chest Seal latest Rescue American North by HyFin Vent Chest Seal latest Rescue American North by $9 HyFin Vent Chest Seal by North American Rescue Health Household Health Care First Aid

HyFin Vent Factory outlet Chest Seal latest Rescue American North by

HyFin Vent Chest Seal by North American Rescue

$9

HyFin Vent Chest Seal by North American Rescue

|||

Product description

The new HyFin Vent Chest Seal provides an additional solution to the treatment of penetrating injuries to the chest by providing an occlusive chest dressing with a patented built-in vent that prevents airflow into the chest cavity during inspiration while allowing air to escape through the vent channel during exhalation. The HyFin Vent Chest Seal is a 6 in. x 6 in. occlusive dressing with built-in vent that provides a superior occlusive chest dressing for those treatment protocols that call for the use of a dressing secured on 3-sides or a vented/valve type chest seal. It features an enhanced adhesive gel formulation that creates a superior seal, even in the most adverse conditions. The seal has a transparent backing to allow placement directly over the wound and easily conforms to the patients chest. The seal is designed with a large, easily-visible red elliptical tab for single step peel-and-apply application that can also facilitate the burping of a wound if necessary. To ensure high quality performance, NAR packages each chest seal using its signature Red Tip Technology red tear notches in a rugged, easy-to-open, foil pouch. The HyFin Vent Chest Seal is made in America and is 100% latex free. Special Features: Large size (6 in. x 6 in.) Patented vent built into the dressing U.S. Patent 7,504,549 amp; Patent(s) Pending Advanced adhesive technology Over-sized red elliptical tab for single step, easy to use, peel-and-apply application Conforms to the casualty's chest Effective in extreme environments Latex free Made in America Dimensions: 4.625" H x 7.5" W x 0.1" D (packaged) Dimensions: 6.0" H x 6.0" W x 0.1" D (chest seal)

HyFin Vent Chest Seal by North American Rescue

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA